Silver Book Fact

The rate of hospitalization from heart failure before and after transcatheter mitral valve repair (TMVR) decreases 73% (per patient year) in patients at prohibitive surgical risk.

Lim D, Reynolds M, Feldman T, Kar S, et al. Improved Functional Status and Quality of Life in Prohibitive Surgical Risk Patients with Degenerative Mitral Regurgitation After Transcatheter Mitral Valve Repair. J Am Coll Cardiol. 2014; 64(2). https://www.ncbi.nlm.nih.gov/pubmed/24184254

Reference

Title
Improved Functional Status and Quality of Life in Prohibitive Surgical Risk Patients with Degenerative Mitral Regurgitation After Transcatheter Mitral Valve Repair
Publication
J Am Coll Cardiol
Publication Date
2014
Authors
Lim D, Reynolds M, Feldman T, Kar S, et al.
Volume & Issue
Volume 64, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Survival rates of patients ages 65-75 with valve repair and replacement
     
  • Spending $1,000 per year on anticoagulants can save $100,000 in hospital costs for care of a person disabled by a stroke.  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Between 1998 and 2008, the rate of death attributable to cardiovascular disease declined 30.6%.  
  • Death Rates for Coronary Heart Disease, 1950-1998